Liu Zheran, Chen Ye, Su Yonglin, Hu Xiaolin, Peng Xingchen
Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Department of Medical Oncology, Cancer Center, the State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Front Oncol. 2021 Nov 29;11:635737. doi: 10.3389/fonc.2021.635737. eCollection 2021.
Nasopharyngeal carcinoma (NPC) is a severe malignancy arising from the nasopharyngeal epithelium and is southern China's third most common cancer. With the advancement of treatment methods, early-stage NPC patients usually have a better prognosis and more prolonged survival period than those with other malignant tumors. Most treatment failures are due to distant metastasis or a locally advanced stage of NPC in the initial diagnosis. In addition, approximately 10% of patients develop local recurrence, and 10%-20% of patients experience distant metastasis after treatment. These patients have a poor prognosis, with a median survival of only approximately 10-15 months. In the rapid development of treatment options, the efficacy and safety of some treatments have been validated and approved for first-line treatment, while those of other treatments remain unclear. The present study aims to provide a comprehensive overview of recent advances in NPC treatment and explain the various therapeutic possibilities in treating locally advanced, recurrent, and metastatic NPC patients.
鼻咽癌（NPC）是一种起源于鼻咽上皮的严重恶性肿瘤，是中国南方第三大常见癌症。随着治疗方法的进步，早期鼻咽癌患者通常比其他恶性肿瘤患者预后更好，生存期更长。大多数治疗失败是由于远处转移或初诊时鼻咽癌处于局部晚期。此外，约10%的患者会出现局部复发，10%-20%的患者在治疗后会发生远处转移。这些患者预后较差，中位生存期仅约10-15个月。在治疗方案迅速发展的过程中，一些治疗的疗效和安全性已得到验证并被批准用于一线治疗，而其他治疗的疗效和安全性仍不明确。本研究旨在全面概述鼻咽癌治疗的最新进展，并解释治疗局部晚期、复发和转移性鼻咽癌患者的各种治疗可能性。
